CEO John T. Treace Continues Open Market Stock Purchases
TMCI has more than doubled off its 52-week low of $1.17.
Summary
TREACE MEDICAL CONCEPTS, INC. CEO John T. Treace purchased an additional $340,589 of company stock in open market transactions, continuing a pattern of insider buying.
Key Events · Ownership and Investor Activity · TMCI
-
CEO Open Market Purchase
CEO John T. Treace acquired 115,520 shares of common stock for a total value of $340,589 through open market transactions between May 26 and May 28, 2026. The purchase prices ranged from $2.79 to $3.02 per share.
-
Reinforced Insider Confidence
This latest purchase by the CEO follows a previous significant open market acquisition earlier in May, indicating a sustained and strong conviction in the company's valuation and future performance by a key insider.
Analysis · TMCI · Industrial Applications And Services
CEO John T. Treace has made additional open market purchases of company stock, totaling over $340,000. This follows a previous significant purchase earlier this month, reinforcing a strong signal of insider confidence. Repeated buying by a key executive, especially the CEO, suggests a belief in the company's future prospects, particularly after recent Q1 results showed a revenue decline but an EPS beat.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 30.2% of the 1644 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.49%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, TMCI was trading at $3.16 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $199.8M. The 52-week trading range was $1.17 to $7.78. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.